Search

Your search keyword '"Dubashi Biswajit"' showing total 521 results
Start Over Author "Dubashi Biswajit"
521 results on '"Dubashi Biswajit"'

52. Modified neoadjuvant clinicopathological risk stratification as a prognostic score in early and locally advanced triple-negative breast cancer

Author

Dubashi, Biswajit, Matta, Kirankumar, Kayal, Smita, Thumathy, Divya, Nisha, Yadav, Dharanipragada, Kadambari, Gunaseelan, Karunanithi, Toi, Pampa Ch, and Ganesan, Prasanth

Subjects
Drug therapy, Risk factors, Prognosis, Patient outcomes, Methods, Neoadjuvant therapy -- Patient outcomes, Triple negative breast cancer -- Drug therapy -- Prognosis, Cancer staging -- Methods, Cancer metastasis -- Risk factors, Metastasis -- Risk factors, Tumor staging -- Methods
Published
2022

53. A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo.

Author

Kuduvalli, Shreyas S., Daisy, Precilla S., Vaithy, Anandraj, Purushothaman, Mugilarasi, Muralidharan, Arumugam Ramachandran, Agiesh, Kumar B., Mezger, Markus, Antony, Justin S., Subramani, Madhu, Dubashi, Biswajit, Biswas, Indrani, Guruprasad, K. P., and Anitha, T. S.

Subjects
EPIGALLOCATECHIN gallate, METFORMIN, CENTRAL nervous system tumors, GLIOMAS, TUMOR growth, CELL analysis
Abstract

Glioma is the most devastating high-grade tumor of the central nervous system, with dismal prognosis. Existing treatment modality does not provide substantial benefit to patients and demands novel strategies. One of the first-line treatments for glioma, temozolomide, provides marginal benefit to glioma patients. Repurposing of existing non-cancer drugs to treat oncology patients is gaining momentum in recent years. In this study, we investigated the therapeutic benefits of combining three repurposed drugs, namely, metformin (anti-diabetic) and epigallocatechin gallate (green tea-derived antioxidant) together with temozolomide in a glioma-induced xenograft rat model. Our triple-drug combination therapy significantly inhibited tumor growth in vivo and increased the survival rate (50%) of rats when compared with individual or dual treatments. Molecular and cellular analyses revealed that our triple-drug cocktail treatment inhibited glioma tumor growth in rat model through ROS-mediated inactivation of PI3K/AKT/mTOR pathway, arrest of the cell cycle at G1 phase and induction of molecular mechanisms of caspases-dependent apoptosis. In addition, the docking analysis and quantum mechanics studies performed here hypothesize that the effect of triple-drug combination could have been attributed by their difference in molecular interactions, that maybe due to varying electrostatic potential. Thus, repurposing metformin and epigallocatechin gallate and concurrent administration with temozolomide would serve as a prospective therapy in glioma patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

54. Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer

Author

Sandhya, Lakshmi, primary, Devi Sreenivasan, Nirmala, additional, Goenka, Luxitaa, additional, Dubashi, Biswajit, additional, Kayal, Smita, additional, Solaiappan, Manikandan, additional, Govindarajalou, Ramkumar, additional, KT, Harichandrakumar, additional, and Ganesan, Prasanth, additional

Published
2023
Full Text
View/download PDF

56. A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo

Author

Kuduvalli, Shreyas S., primary, Daisy, Precilla S., additional, Vaithy, Anandraj, additional, Purushothaman, Mugilarasi, additional, Ramachandran Muralidharan, Arumugam, additional, Agiesh, Kumar B., additional, Mezger, Markus, additional, Antony, Justin S., additional, Subramani, Madhu, additional, Dubashi, Biswajit, additional, Biswas, Indrani, additional, Guruprasad, K. P., additional, and Anitha, T. S., additional

Published
2023
Full Text
View/download PDF

59. Psychosocial counseling of patients planned for hematopoietic stem-cell transplantation for malignant conditions--practical challenges and solutions from India

Author

Gopal, Vishnu, Kayal, Smita, Dubashi, Biswajit, Menon, Vikas, Veeraiah, Surendran, Sivakumar, C., Jayalakshmi, R., Bandlamudi, Bhanu, Bhattacharjee, Arnab, Dahagama, Sindhu, Kalpana, D., Annadurai, Divya, and Ganesan, Prasanth

Subjects
Psychological aspects, Social aspects, Care and treatment, Hematopoietic stem cell transplantation -- Social aspects -- Psychological aspects, Stem cells -- Social aspects -- Psychological aspects, Health counseling -- Social aspects -- Psychological aspects, Hematopoietic stem cells -- Transplantation
Published
2021

64. Frequency and risk factors of bleomycin-induced pulmonary toxicity in South Indian patients with germ-cell tumors

Author

Thakkar, Dimpal, Ramasamy, Kesavan, Adithan, Subathra, Selvarajan, Sandhiya, and Dubashi, Biswajit

Subjects
Drug therapy, Statistics, Complications and side effects, Risk factors, Demographic aspects, Dosage and administration, Germinoma -- Drug therapy, Lung diseases -- Risk factors -- Statistics -- Demographic aspects, Bleomycin -- Dosage and administration -- Complications and side effects, Germ cell tumors -- Drug therapy
Published
2021

70. A combination of Metformin and Epigallocatechin Gallate Potentiates Glioma Chemotherapyin vivo

Author

Kuduvalli, Shreyas S, primary, Precilla, S Daisy, additional, Vaithy, Anandraj, additional, Purushothaman, Mugilarasi, additional, Muralidharan, Arumugam Ramachandran, additional, Kumar, B Agiesh, additional, Mezger, Markus, additional, Antony, Justin S, additional, Subramani, Madhu, additional, Dubashi, Biswajit, additional, Biswas, Indrani, additional, Guruprasad, K P, additional, and Anitha, T.S, additional

Published
2022
Full Text
View/download PDF

74. Mucocutaneous adverse reactions of cancer chemotherapy and chemoradiation

Author

Naveed, Sheikh, Thappa, Devinder, Dubashi, Biswajit, Pandjatcharam, Jagadeesan, Munisamy, Malathi, and Singh, Nidhi

Subjects
Dosage and administration, Care and treatment, Usage, Complications and side effects, Antineoplastic agents -- Dosage and administration, Cancer patients -- Care and treatment, Chemotherapy -- Usage, Dermatologic agents -- Usage -- Complications and side effects, Lapatinib, Cancer treatment, Cancer, Vincristine, Panitumumab, Cetuximab, Crizotinib
Published
2019

75. Comparison of Efficacy of Aspirin Plus EOX vs. EOX Alone in Patients with Locally Advanced and Metastatic Gastric Cancer: a Randomized Clinical Trial.

Author

Jafa, Esha, L, Charles, Nisha, Yadav, Kate, Vikram, Kayal, Smita, Ganesh, Rajesh Nachiappa, V.C., Sunitha, Ganesan, Prasanth, Penumadu, Prasanth, and Dubashi, Biswajit

Abstract

Purpose: The role of aspirin in cancer prevention has been well defined; the last decade revealed its therapeutic role with improved efficacy when aspirin was added to capecitabine in heavily pre-treated metastatic colorectal cancer. Aspirin affects tumour growth through the PI3K pathway, which regulates apoptosis and autophagy. The objective was to compare the efficacy of aspirin plus epirubicin, oxaliplatin, capecitabine (EOX) chemotherapy versus EOX alone in locally advanced and metastatic gastric cancer. Methods: All patients with advanced gastric cancer reporting to the Department of Medical oncology between March 2017 and May 2019 were screened for study eligibility. They were randomly assigned to standard EOX with or without aspirin at a daily dose of 150 mg. Tumour measurements were assessed at baseline and after 3–4 cycles by an independent blinded radiologist according to RECIST criteria 1.1. Toxicity profiles were recorded as per CTCAE v 4.03. Per-protocol group was identified as 70 patients. The primary endpoint was overall response rates in the per-protocol group (defined as patients who received a minimum of 3 cycles and had an evaluable response after randomization). The secondary endpoints included toxicity analysis, progression-free survival, and overall survival. Results: Ninety-five patients who fulfilled the study inclusion and exclusion criteria were randomized to group 1 EOX (50) or group 2 EOX plus aspirin (45). Seventy patients were included for the per-protocol analysis. The overall response rate in group 1 was 27% compared to group 2, which was 42%, P = 0.176. The median duration of follow was 29 (18.56–39.45) months. The median overall survival (n = 95) of group 1 versus group 2 was 11 (8.58–13.42) months and 10 (6.86–13.14) months, respectively, P = 0.90. There was no statistical significance in the overall survival per-protocol analysis (n = 70) between group one 12 (8.75–15.25) months versus group two 12 (6.21–17.79) months, P = 0.50. Conclusions: There was no improvement in the response rates, progression-free survival, and overall survival on adding aspirin to EOX chemotherapy in locally advanced and metastatic gastric cancer in an unselected population. A further role of PI3K mutation as a biomarker needs to be evaluated in this setting. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

81. Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (pRISM) of the Hematology Cancer Consortium (HCC)

Author

Smita Kayal, Hasmukh Jain, Lingaraj Nayak, Jayashree Thorat, Jina Bhattacharyya, Damodar Das, Sewali Deka Talukdar, Dinesh Bhurani, Rayaz Ahmed, Narendra Agrawal, Dubashi Biswajit, Prasanth Ganesan, Chandran K. Nair, Vineetha Raghavan, Manuprasad A, Uday Kulkarni, Sushil Selvarajan, Jayachandran PK, Parathan Karunakaran, Sadashivudu Gundeti, Kundan Mishra, Sharat Damodar, Bharath Ram S, Atul Sharma, Suvir Singh, M. Joseph John, Gaurav Prakash, Smitha Carol Saldanha, Chepsy C Philip, Prashant Mehta, Thenmozhi Mani, Om Prakash, Marimuthu S, Jeyaseelan Lakshmanan, Manju Sengar, Vikram Mathews, and Rajan Kapoor

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

82. Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial

Author

Aby Abraham, Hasmukh Jain, Jina Bhattacharyya, Dubashi Biswajit, Jayachandran PK, Dinesh Bhurani, Stalin Chowdary Bala, Suman Pramanik, Santhosh Devadas, Uday Prakash Kulkarni, Manju Sengar, Rayaz Ahmed, Thenmozhi Mani, Damodar Das, Parathan Karunakaran, Sadashivudu Gundeti, Rasmi Pallasseri, Nikhil Patkar, Manjunath Nookala, Smita Kayal, and Poonkuzhali Balasubramanian

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

85. Post-chemotherapy Changes in Bone Marrow in Acute Leukemia With Emphasis on Detection of Residual Disease by Immunohistochemistry

Author

Ayyanar, Pavithra, Kar, Rakhee, Dubashi, Biswajit, and Basu, Debdatta

Subjects
serous atrophy, remission, bone marrow regeneration, Pathology, stromal changes, residual disease, post-induction chemotherapy, General Engineering, Hematology, trephine biopsy, acute leukemia, dyspoiesis, histomorphology of bone marrow
Abstract

Introduction In acute leukemia, the leading cause of treatment failure is disease relapse leading to a low level of complete remission and short overall survival. Post-chemotherapy marrow examination gives vital clues regarding treatment response and marrow regeneration. Aim We aimed to study the histomorphological changes in post-chemotherapy bone marrow in acute leukemias, monitor residual disease by immunohistochemistry (IHC) on trephine biopsy, and correlate survival status. Method This study was a prospective clinical study. A total of 155 post-induction cases (acute myeloid leukemia [AML] - 68 and acute lymphoblastic leukemia [ALL] - 87), from January 2014 to December 2015, were included with a follow-up of 4-28 months. A detailed histomorphology was studied in all cases. IHC was applied in 88 cases of post-induction marrow, which showed morphologic suspicion of an increase in blasts. Observations Post-induction marrow was hypercellular in 55.9% of AML and normocellular in 56.3% of ALL. Regenerative hematopoiesis was noted in 37.4% of AML and 88.5% of cases of ALL. Marrow serous atrophy and stromal edema were associated with delayed recovery of counts and their recovery duration ranged from one to five months. Twenty-seven bone marrow aspirates were unsatisfactory, and their trephine biopsies were showed remission in 20 cases and stromal changes in nine cases. In addition, trephine biopsy picked up residual leukemic blasts in four cases in which aspirate showed remission status. Post-induction marrow IHC with scattered positivity for blasts showed sustained remission in 96% cases, and in those with clustered positivity, 28.6% showed residual disease, and 7.2% showed relapse at the end of the study period. The median survival duration was 13, 3, and 12 months for cases with sustained remission, residual disease, and relapse, respectively. There was a statistically significant difference in median survival of patients in the three groups (sustained remission, residual disease, and relapse) (p=0.000). Conclusion We conclude that histomorphology augmented by IHC on trephine biopsy gives valuable information regarding post-chemotherapy changes and residual disease status. Bone marrow trephine biopsy is an important tool to assess the remission status of patients with acute leukemia.

Published
2021
Full Text
View/download PDF

89. Outcome of CBV (Carmustine, Cyclophosphamide, Etoposide) Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma: A Retrospective Study from a Tertiary Cancer Center in South India

Author

Krishnamoorthi, Narendran, additional, Prakash, Bhanu, additional, KM, Dhanraju, additional, Pani, Chinmaya Kumar, additional, Ram, Malliha, additional, Rajesh, Kalpana, additional, Dubashi, Biswajit, additional, Ganesan, Prasanth, additional, and Kayal, Smita, additional

Published
2022
Full Text
View/download PDF

93. Randomized phase III trial comparing Daunorubicin and ara-C (DA) versus ara-C, Daunorubicin, and Etoposide (ADE) as induction chemotherapy in pediatric acute myeloid leukemia (InPOG-AML-16-01)

Author

Radhakrishnan, Venkatraman, primary, Bakhshi, Sameer, additional, Kayal, Smita, additional, Thampy, Cherian, additional, Batra, Ankit, additional, Shenoy, Praveen Kumar, additional, Kumar, Hemanth, additional, Chaudhary, Shilpi, additional, Rajaraman, Swaminathan, additional, Bisht, Reema, additional, Dubashi, Biswajit, additional, and Ganesan, Trivadi S., additional

Published
2022
Full Text
View/download PDF

94. Covid-19 Infection in Hematological Malignancies: Registry Data from India

Author

Jain, Arihant, primary, Nayak, Lingaraj, additional, Kulkarni, Uday Prakash, additional, Mehra, Nikita, additional, Yanamandra, Uday, additional, Kayal, Smita, additional, Damodar, Sharat, additional, M John, Joseph, additional, Singh, Suvir, additional, Mehta, Prashant, additional, Munot, Pritesh, additional, Selvarajan, Sushil, additional, Radhakrishnan, Venkatraman, additional, Kapoor, Rajan, additional, Dubashi, Biswajit, additional, Ram S, Bharath, additional, Jain, Hasmukh, additional, PK, Jayachandran, additional, Lakshmanan, Jeyaseelan, additional, Mani, Thenmozhi, additional, Prakash, Om, additional, Thorat, Jayashree, additional, Das, Satyaranjan, additional, George, Biju, additional, Lad, Deepesh, additional, and Malhotra, Pankaj, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results